Kornitzer Capital Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.12M | Sell |
23,359
-85,733
| -79% | -$3.68M | 0.02% | 422 |
|
|
2026
Q1 | $4.01M | Sell |
109,092
-59,053
| -35% | -$2.8M | 0.09% | 220 |
|
|
2025
Q4 | $8.56M | Buy |
168,145
+9,100
| +6% | +$465K | 0.18% | 125 |
|
|
2025
Q3 | $8.83M | Buy |
159,045
+2,962
| +2% | +$173K | 0.18% | 131 |
|
|
2025
Q2 | $10.8M | Buy |
156,083
+225
| +0.1% | +$15.3K | 0.22% | 121 |
|
|
2025
Q1 | $10.8M | Buy |
155,858
+396
| +0.3% | +$32.7K | 0.22% | 119 |
|
|
2024
Q4 | $13.4M | Sell |
155,462
-749
| -0.5% | -$81K | 0.26% | 101 |
|
|
2024
Q3 | $18.6M | Buy |
156,211
+46
| +0% | +$6.13K | 0.34% | 77 |
|
|
2024
Q2 | $22.3M | Buy |
156,165
+947
| +0.6% | +$125K | 0.42% | 54 |
|
|
2024
Q1 | $19.9M | Hold |
155,218
| – | – | 0.37% | 68 |
|
|
2023
Q4 | $16.1M | Buy |
155,218
+1,146
| +0.7% | +$113K | 0.31% | 87 |
|
|
2023
Q3 | $14M | Hold |
154,072
| – | – | 0.29% | 98 |
|
|
2023
Q2 | $12.5M | Hold |
154,072
| – | – | 0.25% | 128 |
|
|
2023
Q1 | $12.3M | Hold |
154,072
| – | – | 0.24% | 127 |
|
|
2022
Q4 | $10.4M | Sell |
154,072
-70
| -0% | -$4.1K | 0.21% | 148 |
|
|
2022
Q3 | $7.68M | Buy |
154,142
+2,070
| +1% | +$111K | 0.16% | 198 |
|
|
2022
Q2 | $8.47M | Hold |
152,072
| – | – | 0.17% | 193 |
|
|
2022
Q1 | $8.44M | Buy |
152,072
+72
| +0% | +$3.69K | 0.14% | 219 |
|
|
2021
Q4 | $8.51M | Hold |
152,000
| – | – | 0.13% | 234 |
|
|
2021
Q3 | $7.3M | Hold |
152,000
| – | – | 0.11% | 249 |
|
|
2021
Q2 | $6.37M | Hold |
152,000
| – | – | 0.1% | 258 |
|
|
2021
Q1 | $5.12M | Sell |
152,000
-232
| -0.2% | -$8.26K | 0.08% | 267 |
|
|
2020
Q4 | $5.32M | Hold |
152,232
| – | – | 0.09% | 265 |
|
|
2020
Q3 | $5.29M | Buy |
152,232
+232
| +0.2% | +$7.73K | 0.1% | 250 |
|
|
2020
Q2 | $4.98M | Buy |
152,000
+30,000
| +25% | +$957K | 0.1% | 252 |
|
|
2020
Q1 | $3.67M | Buy |
122,000
+29,860
| +32% | +$889K | 0.09% | 252 |
|
|
2019
Q4 | $2.67M | Buy |
92,140
+10,140
| +12% | +$281K | 0.05% | 311 |
|
|
2019
Q3 | $2.12M | Buy |
+82,000
| New | +$2.07M | 0.04% | 332 |
|
|
2015
Q1 | – | Sell |
-18,000
| Closed | -$381K | – | 457 |
|
|
2014
Q4 | $381K | Buy |
18,000
+3,500
| +24% | +$78.2K | ﹤0.01% | 382 |
|
|
2014
Q3 | $345K | Buy |
14,500
+1,500
| +12% | +$34.5K | ﹤0.01% | 372 |
|
|
2014
Q2 | $300K | Hold |
13,000
| – | – | ﹤0.01% | 380 |
|
|
2014
Q1 | $297K | Hold |
13,000
| – | – | ﹤0.01% | 395 |
|
|
2013
Q4 | $240K | Buy |
+13,000
| New | +$227K | ﹤0.01% | 400 |
|
Other funds holding NVO
F
Kornitzer Capital Management's NVO Position: Q2 2026 in Review
Kornitzer Capital Management reduced its Novo Nordisk (NVO) stake by 79% in Q2 2026, selling an estimated $3.68M and leaving 23,359 shares worth $1.12M. The position accounts for 0.02% of the portfolio, ranked #422.
Kornitzer Capital Management first reported a position in NVO in Q4 2013 and has held it in 33 quarters since. The position peaked at $22.3M in Q2 2024. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Kornitzer Capital Management held 23,359 shares of Novo Nordisk worth $1.12M as of Q2 2026.
- Kornitzer Capital Management sold 85,733 Novo Nordisk shares in Q2 2026, an estimated $3.68M.
- Novo Nordisk made up 0.02% of Kornitzer Capital Management's portfolio in Q2 2026, its #422 holding.
- Kornitzer Capital Management first reported a position in Novo Nordisk in Q4 2013 and has held it in 33 quarters since.
- Kornitzer Capital Management's Novo Nordisk position peaked at $22.3M in Q2 2024.
- 1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Kornitzer Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.